RX
Recursion Pharmaceuticals
RXRX · NASDAQ
$3.63 +6.45% (+$0.22)
1M +14.15%
Market Cap $1.80B
P/E Ratio -
Div. Yield -
ROE 50.41%
Piotroski F-Score Weak
3/9Valuation
44 /100
Fair P/B 1.97x
P/S 32.90x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 32.53%
Rev. growth 23.46%
FCF growth N/A
Profitability
0 /100
Weak Net margin 945.92%
Op. margin 991.72%
FCF margin 645.82%
Quality
1 /100
Poor ROE 50.41%
ROA 42.79%
Asset turnover 0.05x
Debt
69 /100
Low Current ratio 5.03x
Int. coverage -350.41x
Debt/Equity 0.07x
Stability
75 /100
Stable Rev. volatility 12.06%
EPS volatility 15.90%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na RXRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Najat Khan
Employees
600
Headquarters
Salt Lake City
Nadcházející události
04 LIS
Earnings
Upcoming earnings report